Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Pharma GmbH
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient's treatment must be in accordance with the local marketing authorization (MA) for Vimpat®
The decision to prescribe Vimpat® has to be made by the physician before and independently of his/her decision to include the patient in the study
The Vimpat® treatment should have been started not longer than 2 weeks before study inclusion of the patient
The patient must have a diagnosis of Epilepsy with Partial-Onset Seizures
Based on the physician's clinical judgment, the patient's seizure activity is not controlled sufficiently on a current monotherapy and it is in the patient's best interest to be prescribed adjunctive Vimpat®
You may not be if
In accordance with the Summary of Product Characteristics (SmPC)
